For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
June 25, 2001
- WORLD NEWS IN BRIEF
June 25, 2001
- Profitability Higher for Medical Equipment Importers Than Manufacturers: Survey
June 25, 2001
- Fukuda Denshi to Boost Sales to \100 Billion in 2010
June 25, 2001
- JMA President Criticizes Ceiling System for Medical Costs
June 25, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 25, 2001
- Drug Dispensing Costs Outgrow Bungyo: JMA
June 25, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 25, 2001
- REGULATORY NEWS IN BRIEF -2-
June 25, 2001
- Information on Physicians Most Wanted by Citizens: Survey
June 25, 2001
- REGULATORY NEWS IN BRIEF -1-
June 25, 2001
- Korosho Survey Shows Hypertension, Hyperlipidemia Increasing in Men Aged 30 to 50
June 25, 2001
- CEFP Calls For Review of Public Health Insurance Coverage
June 25, 2001
- More Disclosure Needed for Patient-oriented Medical Services: HPB Director General
June 25, 2001
- FPMAJ Proposes Authorized Price Reimbursement Method
June 25, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
June 25, 2001
- Ordinary Profit Ratio Averages 18.2% for 27 Listed Firms
June 25, 2001
- BUSINESS NEWS IN BRIEF -2-
June 25, 2001
- BUSINESS NEWS IN BRIEF -1-
June 25, 2001
- Globalization of Japanese Firms Discussed: UBS Warburg Conference
June 25, 2001
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…